Multani PS - Search Results

1

A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia.

Lancet JE, Baer MR, Duran GE, List AF, Fielding R, Marcelletti JF, Multani PS, Sikic BI. Lancet JE, et al. Among authors: multani ps. Leuk Res. 2009 Aug;33(8):1055-61. doi: 10.1016/j.leukres.2008.09.015. Epub 2008 Dec 23. Leuk Res. 2009. PMID: 19108889 Clinical Trial.

2

Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia.

Marcelletti JF, Multani PS, Lancet JE, Baer MR, Sikic BI. Marcelletti JF, et al. Among authors: multani ps. Leuk Res. 2009 Jun;33(6):769-74. doi: 10.1016/j.leukres.2008.09.020. Epub 2008 Oct 30. Leuk Res. 2009. PMID: 18976810 Clinical Trial.

3

Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma.

Nabhan C, Peterson LA, Kent SA, Tallman MS, Dewald G, Multani P, Gordon LI. Nabhan C, et al. Leuk Lymphoma. 2002 Nov;43(11):2145-9. doi: 10.1080/1042819021000032971. Leuk Lymphoma. 2002. PMID: 12539741

4

Rituximab.

Multani P, White CA. Multani P, et al. Cancer Chemother Biol Response Modif. 2003;21:235-58. Cancer Chemother Biol Response Modif. 2003. PMID: 15338748 Review. No abstract available.

5

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA. Witzig TE, et al. J Clin Oncol. 2002 May 15;20(10):2453-63. doi: 10.1200/JCO.2002.11.076. J Clin Oncol. 2002. PMID: 12011122 Clinical Trial.

6

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-López AJ, White CA. Wiseman GA, et al. Among authors: multani ps. Blood. 2002 Jun 15;99(12):4336-42. doi: 10.1182/blood.v99.12.4336. Blood. 2002. PMID: 12036859 Free article. Clinical Trial.

7

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA. Witzig TE, et al. Among authors: multani ps. J Clin Oncol. 2002 Aug 1;20(15):3262-9. doi: 10.1200/JCO.2002.11.017. J Clin Oncol. 2002. PMID: 12149300 Clinical Trial.

8

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.

Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, Lister J, Multani PS. Witzig TE, et al. Among authors: multani ps. J Clin Oncol. 2003 Apr 1;21(7):1263-70. doi: 10.1200/JCO.2003.08.043. J Clin Oncol. 2003. PMID: 12663713

9

Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma.

Multani P. Multani P. Int J Hematol. 2002 Dec;76(5):401-10. doi: 10.1007/BF02982805. Int J Hematol. 2002. PMID: 12512834 Review.

10

Non-Hodgkin's lymphoma: review of conventional treatments.

Multani P, White CA, Grillo-López A. Multani P, et al. Curr Pharm Biotechnol. 2001 Dec;2(4):279-91. doi: 10.2174/1389201013378581. Curr Pharm Biotechnol. 2001. PMID: 11762410 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters